2,3-dimethyl-7-oxa-bicyclo[2.2.1]heptane-2,3-dicarboxylic acid anhydride | 10385-74-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃类
• 英文名称: 2,3-dimethyl-7-oxa-bicyclo[2.2.1]heptane-2,3-dicarboxylic acid anhydride
• 英文别名: Cantharidin；Hexahydro-3a,7a-dimethyl-4,7-epoxyisobenzofuran-1,3-dione；2,6-dimethyl-4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione
• CAS: 10385-74-7
• 化学式: C₁₀H₁₂O₄
• mdl: MFCD00044767
• 分子量: 196.203
• InChiKey: DHZBEENLJMYSHQ-UHFFFAOYSA-N

物化性质

• 熔点：
  217 °C
• 沸点：
  326.9±35.0 °C(Predicted)
• 密度：
  1.362±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  氯磺酸 、 2,3-dimethyl-7-oxa-bicyclo[2.2.1]heptane-2,3-dicarboxylic acid anhydride 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Meyer,H., Monatshefte fur Chemie, 1898, vol. 19, p. 709

  摘要：

  DOI：
• 作为产物：
  描述：

  4,6-二氢-1h,3h-噻吩并[3,4-c]呋喃-1,3-二酮 在 palladium 10% on activated carbon 、 氢气 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 20.0 ℃ 、1400.03 MPa 条件下， 生成 2,3-dimethyl-7-oxa-bicyclo[2.2.1]heptane-2,3-dicarboxylic acid anhydride
  参考文献：
  名称：

  Compositions and methods for the protection of nucleophilic groups

  摘要：

  本发明提供了与保护和去保护包含亲核基团的分子有关的组合物、方法和试剂盒，例如保护和去保护热稳定聚合酶。还提供了根据本发明保护的聚合酶进行核酸扩增的方法。

  公开号：

  US09222127B2

文献信息

• COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS
  申请人：Gasser Robin Beat

  公开号：US20100137294A1

  公开（公告）日：2010-06-03

  The present application discloses the Tv-stp-1 serine/threonine phosphatase gene from Trichostrongylus vitrinus , and compounds that are useful as invertebrate control agents.

  本申请披露了Trichostrongylus vitrinus的Tv-stp-1丝氨酸/苏氨酸磷酸酶基因以及作为无脊椎动物控制剂有用的化合物。
• Methods of Treating Disorders Associated with Protein Aggregation
  申请人：Pak Stephen C.

  公开号：US20130024953A1

  公开（公告）日：2013-01-24

  The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a Caenorhabditis elegans model system. According to the invention, treatment with one or more of these APA compounds may be used to ameliorate the symptoms and signs of AT deficiency as well as other disorders marked by protein aggregation, including, but not limited to, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.

  本发明涉及与蛋白质聚集相关的临床疾病的治疗方法，包括向受试者施用来自以下组中选择的抗蛋白质聚集（“APA”）化合物的有效量：哌唑酮，氟哌利多（例如氟哌利多盐酸盐），他莫昔芬（例如他莫昔芬柠檬酸盐），紫杉醇，蝉蜕素，蝉酸及其盐和结构相关化合物。本发明至少部分基于以下发现：上述每种化合物均能促进Caenorhabditis elegans模型系统中聚集的ATZ蛋白的降解。根据本发明，使用这些APA化合物之一或多个进行治疗，可用于缓解AT缺陷以及其他由蛋白质聚集标记的疾病的症状和体征，包括但不限于阿尔茨海默病、帕金森病和亨廷顿病。
• Methods of treating disorders associated with protein aggregation
  申请人：Pak Stephen C.

  公开号：US09072772B2

  公开（公告）日：2015-07-07

  The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a Caenorhabditis elegans model system. According to the invention, treatment with one or more of these APA compounds may be used to ameliorate the symptoms and signs of AT deficiency as well as other disorders marked by protein aggregation, including, but not limited to, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.

  本发明涉及与蛋白质聚集相关的临床障碍治疗方法，包括向受试者投与有效量的抗蛋白质聚集（“APA”）化合物，所述化合物选自以下组合：哌嗪、氟苯那嗪（例如，氟苯那嗪盐酸盐）、他莫昔芬（例如，他莫昔芬柠檬酸盐）、紫杉醇、鲨鱼毒素、鲨鱼毒酸及其结构相关化合物。本发明至少部分基于发现，上述化合物均能促进秀丽隐杆线虫模型系统中聚集的ATZ蛋白降解。根据本发明，使用这些APA化合物之一或多个的治疗可用于缓解AT缺乏症状和体征，以及其他蛋白质聚集标志的障碍，包括但不限于阿尔茨海默病、帕金森病和亨廷顿病。
• METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN AGGREGATION
  申请人：University Of Pittsburgh - of the Commonwealth System of Higher Education

  公开号：US20150265626A1

  公开（公告）日：2015-09-24

  The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a Caenorhabditis elegans model system. According to the invention, treatment with one or more of these APA compounds may be used to ameliorate the symptoms and signs of AT deficiency as well as other disorders marked by protein aggregation, including, but not limited to, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.

  本发明涉及治疗与蛋白质聚集相关的临床疾病的方法，包括向受试者施用来自以下组中选择的抗蛋白质聚集（“APA”）化合物的有效量：哌唑酮，氟苯奈嗪（例如，氟苯奈嗪盐酸盐），他莫昔芬（例如，他莫昔芬柠檬酸盐），紫杉醇，鲍鱼毒素，鲍鱼毒酸，其盐及其结构相关化合物。该发明至少部分基于以下发现：上述每种化合物均能够促进在秀丽隐杆线虫模型系统中聚集的ATZ蛋白质的降解。根据本发明，使用这些APA化合物中的一个或多个进行治疗可以用于改善AT缺乏症状和体征以及其他以蛋白质聚集为特征的疾病，包括但不限于阿尔茨海默病、帕金森病和亨廷顿病。
• Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives
  申请人：Verrica Pharmaceuticals, Inc.

  公开号：US10745413B2

  公开（公告）日：2020-08-18

  The present disclosure provides methods for synthesizing cantharidin and cantharidin derivatives.

  本公开提供了合成可他利定和可他利定衍生物的方法。